Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The potential sale is playing out against a larger deal as Australian rival BHP has offered to buy parent Anglo American for $39 billion.
Cars with Drive Pilot are only available for sale in California and Nevada, and even there it only works on certain freeways.
The company says a turnaround will take time as the market for luxury goods cools and China muddles through economic doldrums.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Despite Humane’s lofty dreams to disrupt the smartphone status quo, critics have not been thrilled with the startup’s debut device.
GM said it grew market share across several pickup and SUV models, despite pricing incentives that were “well below” the industry average.
Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
A new survey finds evidence that “the drugs have a meaningful impact on consumer behavior and spending on groceries and restaurants.”
Shares are at a 15-month low amid a pile-up of bad news, as analysts call for a course correction, and production woes continue to mount.
Experts testified in one hearing about whether the company had improved safety and compliance procedures since two major crashes.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.